The research essay on PT-141 (Bremelanotide) below may intrest you, or you can click here to read more research we have put together on our blog.
PT-141 (Bremelanotide) carries a half-life of 120 minutes, a molecular formula of C50H68N14O10, and a molecular weight of 1025.2. It is a research cyclic peptide that has been shown to have ties to reperfusion injury and hemorrhagic shock.
Previous scientific study that was conducted on animal test subjects in relation to PT-141 (Bremelanotide) overall functionality primarily focused on determining whether or not the peptide induced lordosis; a sexual response that is essentially defined by an animal’s willingness and desire to mate. Some of these original studies remain intact today, as some focus of study regarding PT-141 (Bremelanotide) is reserved to test its connection with various forms of male and female dysfunction, including the activation and lessening of sexual drive.
Today, most of the scientific study on animal test subjects relating to PT-141 (Bremelanotide) primarily focuses on its relationship with managing reperfusion injury and hemorrhagic shock.
The reason for this shift of focus has a lot to do with the inherent functionality that PT-141 (Bremelanotide) has been shown to display. In essence, the peptide has been shown to stimulate the melanocortin receptors MC3-R and MC4-R in the central nervous system. This engagement enables the peptide to block and regulate specific signals which relate to negative body functions such as inflammation and blood flow restriction. This type of receptor activation is tied to a modulation of inflammation and a limiting of ischemia; a condition that is marked by restrictive blood flow. As such, scientific study that has been conducted on animal test subjects has been able to determine that PT-141 (Bremelanotide) is able to curb bodily irritation that is triggered by various pathogens and irritants, and it can act to minimize damage or dysfunction of blood vessels and associated tissues.
Because of the way in which PT-141 (Bremelanotide) has been shown to function in relation to limit damage related to ischemia, scientific study that has been based on animal test subjects has determined that can play a key role in the lowering or even the prevention of reperfusion injury; a condition that is marked by damage caused when blood supply reenters into the tissue after an interval of lack of oxygen or ischemia, such as a stroke. The resultant absence of nutrients and oxygen from blood during this period produces a condition in which the restoration of circulation actually causes damage and inflammation as opposed to restoring proper functionality. The condition has also been shown to play a rather critical part in the brain’s ischemic cascade; that is, the series of biochemical reactions that are instigated in the brain seconds or minutes after an instance of ischemia is detected. However, scientific study based on animal test subjects has determined that PT-141 (Bremelanotide) works neurologically to lessen the inhibitions that are typically associated with blood flow restriction to tissues as a result of the ischemic cascade. This action in turn lessens or even prohibits the resultant damage that otherwise may come about from a limitation of blood flow in potentially affected areas.
Scientific study that has been conducted on animal test subjects has also determined that PT-141 (Bremelanotide)’s design allows it to aid in the event of a hemorrhagic shock, a condition where lowered tissue perfusion results in an inadequate delivery of the oxygen and nutrients needed to proper cellular homeostasis. It is a potentially serious condition, and one that can be somewhat difficult to pinpoint because not all organs and tissues will experience the exact same amount of oxygen imbalance for a specific clinical disturbance. Specifically, PT-141 (Bremelanotide)’s design allows for the stimulation of neural reflexes in order to boost sympathetic outflow to the heart and other organs that may either dramatically slow down or even cease to function as a result of the shock. This process behind PT-141 (Bremelanotide)’s methodology includes the following elements:
Although there has been an extensive amount of research and study conducted in relation to PT-141 (Bremelanotide) and its overall functionality, operational mechanics, and theorized benefits, it needs to be noted that all of the research that has been conducted and the subsequent results from such research has been solely built around the scientific study based on animal test subjects. The peptide is only intended for the use of scientific study at this point in time. Therefore, any findings or observations that relate to PT-141 (Bremelanotide)’s overall functionality, mechanics, or theoretical benefits, should only be contained to the strict confines of a controlled environment such as a medical research facility or a laboratory.